Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 115

1.

The influence of selective vitamin D receptor activator paricalcitol on cardiovascular system and cardiorenal protection.

Duplancic D, Cesarik M, Poljak NK, Radman M, Kovacic V, Radic J, Rogosic V.

Clin Interv Aging. 2013;8:149-56. doi: 10.2147/CIA.S38349. Epub 2013 Feb 11. Review.

PMID:
23430986
[PubMed - indexed for MEDLINE]
Free PMC Article
2.

Emerging role for the vitamin D receptor activator (VDRA), paricalcitol, in the treatment of secondary hyperparathyroidism.

Cozzolino M, Brancaccio D.

Expert Opin Pharmacother. 2008 Apr;9(6):947-54. doi: 10.1517/14656566.9.6.947. Review.

PMID:
18377338
[PubMed - indexed for MEDLINE]
3.

Paricalcitol and cardiorenal outcome: from the IMPACT study to clinical practice.

Bellasi A, Galassi A, Salvi P, Cozzolino M.

Blood Purif. 2013;36(1):12-6. doi: 10.1159/000350579. Epub 2013 May 25. Review.

PMID:
23736115
[PubMed - indexed for MEDLINE]
4.
5.

New acquisitions in therapy of secondary hyperparathyroidism in chronic kidney disease and peritoneal dialysis patients: role of vitamin D receptor activators.

Brancaccio D, Cozzolino M, Pasho S, Fallabrino G, Olivi L, Gallieni M.

Contrib Nephrol. 2009;163:219-26. doi: 10.1159/000223802. Epub 2009 Jun 3.

PMID:
19494617
[PubMed - indexed for MEDLINE]
6.

Role of vitamin d receptor activators in cardio-renal syndromes.

Cozzolino M, Bruschetta E, Stucchi A, Ronco C, Cusi D.

Semin Nephrol. 2012 Jan;32(1):63-9. doi: 10.1016/j.semnephrol.2011.11.009. Review.

PMID:
22365164
[PubMed - indexed for MEDLINE]
7.

Magnetic bead-based proteomic technology to study paricalcitol effect in kidney transplant recipients.

Pérez V, Sánchez-Escuredo A, Lauzurica R, Bayés B, Navarro-Muñoz M, Pastor MC, Cañas L, Bonet J, Romero R.

Eur J Pharmacol. 2013 Jun 5;709(1-3):72-9. doi: 10.1016/j.ejphar.2013.03.040. Epub 2013 Apr 6.

PMID:
23567070
[PubMed - indexed for MEDLINE]
8.

[Vitamin D in the treatment of cardiorenal syndrome in patients with chronic nephropathy].

Kharlamov AN, Perrish AN, Gabiskiĭ IaL, Ronne Kh, Ivanova EIu.

Kardiologiia. 2012;52(3):33-44. Russian.

PMID:
22839442
[PubMed - indexed for MEDLINE]
9.

Vitamin D receptor activator selectivity in the treatment of secondary hyperparathyroidism: understanding the differences among therapies.

Brancaccio D, Bommer J, Coyne D.

Drugs. 2007;67(14):1981-98. Review. Erratum in: Drugs. 2007;67(17):2556.

PMID:
17883283
[PubMed - indexed for MEDLINE]
10.

[Role of paracalcitol in the management of non-dialysis CKD: state of art and... Unmet needs].

Mascia S, Garofalo C, Donnarumma G, Di Pietro R, Liberti ME, Pacilio M, Sagliocca A, Zamboli P, Minutolo R, Conte G, De Nicola L.

G Ital Nefrol. 2010 Nov-Dec;27(6):616-28. Review. Italian.

PMID:
21132644
[PubMed - indexed for MEDLINE]
11.

Paricalcitol does not improve glucose metabolism in patients with stage 3-4 chronic kidney disease.

de Boer IH, Sachs M, Hoofnagle AN, Utzschneider KM, Kahn SE, Kestenbaum B, Himmelfarb J.

Kidney Int. 2013 Feb;83(2):323-30. doi: 10.1038/ki.2012.311. Epub 2012 Aug 22.

PMID:
22913981
[PubMed - indexed for MEDLINE]
Free PMC Article
12.

The use of group sequential, information-based sample size re-estimation in the design of the PRIMO study of chronic kidney disease.

Pritchett Y, Jemiai Y, Chang Y, Bhan I, Agarwal R, Zoccali C, Wanner C, Lloyd-Jones D, Cannata-Andía JB, Thompson T, Appelbaum E, Audhya P, Andress D, Zhang W, Solomon S, Manning WJ, Thadhani R.

Clin Trials. 2011 Apr;8(2):165-74. doi: 10.1177/1740774511399128.

PMID:
21478328
[PubMed - indexed for MEDLINE]
13.

The impact of paricalcitol on left ventricular hypertrophy.

Cozzolino M, Ronco C.

Contrib Nephrol. 2011;171:161-5. doi: 10.1159/000327170. Epub 2011 May 23. Review.

PMID:
21625106
[PubMed - indexed for MEDLINE]
14.

Shining light on vitamin D trials in chronic kidney disease.

Nigwekar SU, Thadhani RI.

Kidney Int. 2013 Feb;83(2):198-200. doi: 10.1038/ki.2012.415.

PMID:
23364588
[PubMed - indexed for MEDLINE]
Free PMC Article
15.

Oral paricalcitol in the treatment of patients with CKD and proteinuria: a randomized trial.

Fishbane S, Chittineni H, Packman M, Dutka P, Ali N, Durie N.

Am J Kidney Dis. 2009 Oct;54(4):647-52. doi: 10.1053/j.ajkd.2009.04.036. Epub 2009 Jul 12.

PMID:
19596163
[PubMed - indexed for MEDLINE]
16.

Management of secondary hyperparathyroidism in uremic patients: the role of the new vitamin D analogs.

Brancaccio D, Cozzolino M, Galassi A, Chiarelli G, Butti A, Bellasi A, Rocca-Rey L, Volpi A, Anelli A, Zoni U, Fusaro M, Brambilla C, Missaglia E, Crovetto C, Russo M, Longhini C, Provenzano R, Incalcaterra F, Cerasola G, Li Vecchi M, Gallieni M.

J Nephrol. 2007 Jan-Feb;20(1):3-9. Review.

PMID:
17347966
[PubMed - indexed for MEDLINE]
17.

[Vitamin D metabolism and current options for therapeutic activation of vitamin D receptor in patients with chronic kidney disease or renal failure].

Dusilová Sulková S.

Vnitr Lek. 2012 Nov;58(11):839-49. Review. Czech.

PMID:
23256830
[PubMed - indexed for MEDLINE]
18.

Role of vitamin D in chronic kidney disease.

Patel TV, Singh AK.

Semin Nephrol. 2009 Mar;29(2):113-21. doi: 10.1016/j.semnephrol.2009.01.004. Review.

PMID:
19371802
[PubMed - indexed for MEDLINE]
Free PMC Article
19.

Pathogenesis and treatment of secondary hyperparathyroidism in dialysis patients: the role of paricalcitol.

Cozzolino M, Galassi A, Gallieni M, Brancaccio D.

Curr Vasc Pharmacol. 2008 Apr;6(2):148-53. Review.

PMID:
18393917
[PubMed - indexed for MEDLINE]
20.

Chronic kidney disease Markov model comparing paricalcitol to calcitriol for secondary hyperparathyroidism: a US perspective.

Nuijten M, Andress DL, Marx SE, Sterz R.

Curr Med Res Opin. 2009 May;25(5):1221-34. doi: 10.1185/03007990902844097 .

PMID:
19335321
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk